CFS & Fibromyalgia Treatment SSRI/SNRIs for Fibromyalgia and Chronic Fatigue Syndrome By Adrienne Dellwo Adrienne Dellwo LinkedIn Adrienne Dellwo is an experienced journalist who was diagnosed with fibromyalgia and has written extensively on the topic. Learn about our editorial process Updated on May 29, 2022 Medically reviewed by Diana Apetauerova, MD Medically reviewed by Diana Apetauerova, MD LinkedIn Diana Apetauerova, MD, is board-certified in neurology with a subspecialty in movement disorders. She is an associate clinical professor of neurology at Tufts School of Medicine. Learn about our Medical Expert Board Print Table of Contents View All Table of Contents What They Are Serotonin Syndrome Suicide Discontinuation Side Effects/Interactions Reducing Your Risk A Word From Verywell Of all the treatments for fibromyalgia (FMS) and chronic fatigue syndrome (ME/CFS), antidepressants may be the hardest for people to understand. It's common for people to be confused about why these medications are prescribed for conditions other than depression. However, a growing body of evidence shows that antidepressants are effective treatments for FMS, and to a lesser degree, ME/CFS. Antidepressants change the way certain neurotransmitters work in your brain, and the same neurotransmitters are involved in FMS, ME/CFS, and major depressive disorder. Jonathan Nourok / Getty Images The two types of antidepressants that are shown to be most effective against symptoms of FMS are: Selective Serotonin Reuptake Inhibitors (SSRIs) Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) What Are SSRIs and SNRIs? Serotonin and norepinephrine are both neurotransmitters—chemicals in the brain that transmit messages from one neuron (brain cell) to another. Each deals with multiple functions. Serotonin's functions include pain processing and regulation of the sleep cycle. Your brain uses serotonin to create melatonin, which helps you get to sleep. Norepinephrine is involved with the body's stress response, alertness, and memory. Abnormalities in serotonin and norepinephrine are believed to be related to some cases of FMS and ME/CFS. SSRIs/SNRIs make more of them available by slowing down reuptake, which is when they're absorbed back into the nerve cell after use. Of the FDA-approved drugs for FMS, two out of three are SNRIs. (No drugs are FDA-approved for ME/CFS.) They are: Cymbalta (duloxetine) Savella (milnacipran) Other SNRIs are on the market and may be prescribed off-label for these illnesses. They include: Effexor (venlafaxine)Pristiq (desvenlafaxine) SSRIs, which are also sometimes prescribed off-label, include: Celexa (citalopram)Lexapro (escitalopram)Luvox (fluvoxamine)Paxil/Pexeva (paroxetine)Prozac/Sarafem/Selfemra/Rapiflux (fluoxetine)Zoloft (sertraline) Serotonin Syndrome SSRIs, SNRIs, and other medications that increase serotonin can lead to a potentially deadly condition called serotonin syndrome. The risk increases when you take more than one serotonin-increasing substance, which can include prescription medications, recreational drugs, and even certain supplements. To lower your risk of serotonin syndrome, it's important for you to tell your healthcare provider and pharmacist about everything you're taking. Suicide SSRIs, SNRIs, and all other antidepressants are mandated by the FDA to carry a black-box warning–-the agency's most serious alert–-about an increased risk of suicidal thoughts or behaviors in those under 25. It's important for anyone taking these drugs to be aware of the risk, and it's also important for friends and family members to know about it. They may be the ones who spot the warning signs. If you find yourself having suicidal thoughts, get help right away. Here are two hotlines you can call: 1-800-SUICIDE (The Natonal Suicide Prevention Hotline)1-800-784-2433 (The International Association for Suicide Prevention Hotline) You should also talk to your healthcare provider about these thoughts and what the best course of action is. Discontinuation Going off of SSRIs/SNRIs carries its own risks. Stopping too quickly can cause what's called discontinuation syndrome, so you should talk to your healthcare provider about the correct way to gradually wean yourself off of the drug. Symptoms of discontinuation syndrome include: Fatigue Nausea Muscle pain Insomnia Anxiety and agitation Dizziness Sensory disturbances Irritability Tingling sensations Vivid dreams Electric shock sensations Discontinuation symptoms can range from minor to debilitating. Because many of these symptoms are also common in FMS and ME/CFS, you could mistake them for symptoms of your illness that are increasing as you wean off of the medication. Contact your healthcare provider if you have any concerns. Side Effects and Interactions These drugs come with a long list of potential side effects. Some of the more dangerous ones include seizure, hallucination and out-of-control actions. SSRIs/SNRIs can interact negatively with drugs other than those that increase serotonin. These may include anti-inflammatories (NSAIDs), blood thinners, and several others. Side effects and interactions vary by drug. To check on specific drugs, you can look them up at Drugs.com or RxList.com. They're also generally available in packaging information. Reducing Your Risk The best way for you to reduce the risks associated with SSRIs/SNRIs is to carefully follow your healthcare provider's and pharmacist's instructions for both dosage and weaning. In case of emergency, you may also want to keep a list of your medications in your wallet. It can help to print out lists of possible side effects and keep them somewhere visible, especially when you start a new medication. That way, you'll be able to quickly see whether new symptoms you're experiencing may be tied to the drug. A Word From Verywell The decision to take SSRIs or SNRIs is best made by you and your healthcare provider while considering your diagnoses, symptoms, overall health, and lifestyle factors. You may need to try several drugs in this class before you find one that works well for you and that you can tolerate. This can take a lot of time. Be sure to keep the lines of communication with your healthcare provider open during this process. 7 Sources Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. Häuser W, Bernardy K, Uçeyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA. 2009;301(2):198-209. doi:10.1001/jama.2008.944 Commissioner Oof the. Living with Fibromyalgia, Drugs Approved to Manage Pain. U.S. Food and Drug Administration. Jan 31, 2014. Volpi-abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013;13(4):533-40. Nischal A, Tripathi A, Nischal A, Trivedi JK. Suicide and antidepressants: what current evidence indicates. Mens Sana Monogr. 2012;10(1):33-44. doi:10.4103/0973-1229.87287 Gabriel M, Sharma V. Antidepressant discontinuation syndrome. CMAJ. 2017;189(21):E747. doi:10.1503/cmaj.160991 Santos G, Moreira AM. Distressing Visual Hallucinations after Treatment with Trazodone. Case Rep Psychiatry. 2017;2017:6136914. doi:10.1155/2017/6136914 Low Y, Setia S, Lima G. Drug-drug interactions involving antidepressants: focus on desvenlafaxine. Neuropsychiatr Dis Treat. 2018;14:567-580. doi:10.2147/NDT.S157708 Additional Reading Arnold LM, et al. Comparisons of the Efficacy and Safety of Duloxetine for the Treatment of Fibromyalgia in Patients With Versus Without Major Depressive Disorder. The Clinical Journal of Pain. 2009 Jul-Aug;25(6):461-8. Choy EH, et al. Safety and Tolerability of Duloxetine in the Treatment of Patients With Fibromyalgia: Pooled Analysis of Data From Five Clinical Trials. Clinical Rheumatology. 2009 Sep;28(9):1035-44. Derry S, et al. Milnacipran for Neuropathic Pain and Fibromyalgia in Adults. Cochrane Database of Systematic Reviews. 2012 Mar 14;3:CD008244. Nishiyori M, et al. Permanent Relief From Intermittent Cold Stress-induced Fibromyalgia-like Abnormal Pain by Repeated Intrathecal Administration of Antidepressants. Molecular pain. 2011 Sep 21;7:69. Saxe PA, et al. Short-Term (2-Week) Effects of Discontinuing Milnacipran in Patients With Fibromyalgia. Current Medical Research and Opinion. 2012 Mar 19. U.S. Food and Drug Administration. Living with Fibromyalgia. Warner CH, et al. Antidepressant Discontinuation Syndrome. American Family Physician. 2006 Aug 1;74(3):449-56. NIH Publication NO. 04-5326. By Adrienne Dellwo Adrienne Dellwo is an experienced journalist who was diagnosed with fibromyalgia and has written extensively on the topic. See Our Editorial Process Meet Our Medical Expert Board Share Feedback Was this page helpful? Thanks for your feedback! What is your feedback? Other Helpful Report an Error Submit